AXPAXLI (OTX-TKI) - (SOL-1)

September 1, 2026: Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced upcoming September-October 2026 investor and scientific conference participation, including presentations on AXPAXLI/OTX-TKI for retinal disease.

AXPAXLI (OTX-TKI): The company will present “Efficacy and Safety of Intravitreal Axitinib Hydrogel (OTX-TKI) in Neovascular Age-related Macular Degeneration: Results from the Phase 3 SOL-1 Superiority Trial” at The Retina Society 59th Annual Scientific Meeting on September 24, 2026, and again at the 26th Euretina Congress on October 2, 2026. AXPAXLI is described as an investigational axitinib intravitreal hydrogel based on ELUTYX technology and is currently in Phase 3 trials for wet age-related macular degeneration and diabetic retinal disease, including non-proliferative diabetic retinopathy.

Other retina-focused events: Ocular will present corporate retina strategy talks at the Ophthalmology Futures Forums Retina Forum and Euretina Innovation Spotlight on September 30, 2026, and participate in a Euretina symposium on nAMD management and durability on October 2, 2026.

OTX-TIC: The travoprost intracameral hydrogel program has completed Phase 2 in open-angle glaucoma or ocular hypertension; the company said it is evaluating next steps.

Investor events: one-on-one meetings at Wells Fargo’s healthcare conference on September 10 and a Baird fireside chat on September 15, 2026.